pentoxifylline has been researched along with Liver Dysfunction in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of pretreatment with pentoxifylline on normothermic liver ischemia was studied in rats." | 7.69 | [Liver damage due to normothermic ischemia and reperfusion in the rat. The effects of pentoxifylline pretreatment]. ( Castillo Olivares Ramos, JL; Martínez Onturbe, P; Navidad Novalvos, R; Ratia Giménez, T; Santamaría Solís, LV, 1995) |
| "Pentoxifylline is a methylxanthine compound which was first filed in 1973 and registered in 1974 in the United States by Sanofi-Aventis Deustchland Gmbh for the treatment of intermittent claudication for chronic occlusive arterial disease." | 6.50 | Pentoxifylline in liver ischemia and reperfusion. ( Cejalvo, D; García, D; Genovés, P; Lloris-Carsi, JM; Martin, A; Toledo, AH; Toledo-Pereyra, LH; Zaragoza, C, 2014) |
| "Pentoxifylline downregulates the inflammatory response significantly and decreases liver injury in acute endotoxemia." | 3.73 | Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia. ( Coimbra, R; Hoyt, DB; Loomis, W; Melbostad, H; Porcides, RD; Tobar, M; Wolf, P, 2005) |
| "The effect of pretreatment with pentoxifylline on normothermic liver ischemia was studied in rats." | 3.69 | [Liver damage due to normothermic ischemia and reperfusion in the rat. The effects of pentoxifylline pretreatment]. ( Castillo Olivares Ramos, JL; Martínez Onturbe, P; Navidad Novalvos, R; Ratia Giménez, T; Santamaría Solís, LV, 1995) |
| "In this study, to clarify the role of activated macrophages in the augmentation of endotoxin hepatoxicity, rats were pretreated with zymosan, an activator of macrophages, before the induction of endotoxin hepatotoxicity, and some were given pentoxifylline, an inhibitor of tumour necrosis factor production." | 3.69 | Role of activated macrophages in augmentation of endotoxin hepatotoxicity. ( Asaka, S; Nakata, K; Shibayama, Y, 1994) |
| "Severe alcoholic hepatitis (SAH) is defined by modified Maddrey discriminant function ≥32 or Model for End-Stage Liver Disease (MELD) >21 and/or hepatic encephalopathy." | 2.55 | New paradigms in management of alcoholic hepatitis: a review. ( Goyal, O; Kishore, H; Sidhu, S; Sidhu, SS, 2017) |
| "Pentoxifylline is a methylxanthine compound which was first filed in 1973 and registered in 1974 in the United States by Sanofi-Aventis Deustchland Gmbh for the treatment of intermittent claudication for chronic occlusive arterial disease." | 2.50 | Pentoxifylline in liver ischemia and reperfusion. ( Cejalvo, D; García, D; Genovés, P; Lloris-Carsi, JM; Martin, A; Toledo, AH; Toledo-Pereyra, LH; Zaragoza, C, 2014) |
| "The prognosis of acute pancreatitis (AP) depends upon the degree of pancreatic necrosis and the intensity of multisystem organ failure." | 1.35 | Comparative effects of several therapatic agents on hepatic damage induced by acute experimental pancreatitis. ( Eşrefoğlu, M; Gül, M; Turan, F, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Genovés, P | 1 |
| García, D | 1 |
| Cejalvo, D | 1 |
| Martin, A | 1 |
| Zaragoza, C | 1 |
| Toledo, AH | 1 |
| Toledo-Pereyra, LH | 1 |
| Lloris-Carsi, JM | 1 |
| Rocha-Santos, V | 1 |
| Figueira, ER | 1 |
| Rocha-Filho, JA | 1 |
| Coelho, AM | 1 |
| Pinheiro, RS | 1 |
| Bacchella, T | 1 |
| Machado, MC | 1 |
| D'Albuquerque, LA | 1 |
| Sidhu, SS | 1 |
| Goyal, O | 1 |
| Kishore, H | 1 |
| Sidhu, S | 1 |
| Batcioglu, K | 1 |
| Gul, M | 2 |
| Uyumlu, AB | 1 |
| Esrefoglu, M | 2 |
| Petrowsky, H | 1 |
| Breitenstein, S | 1 |
| Slankamenac, K | 1 |
| Vetter, D | 1 |
| Lehmann, K | 1 |
| Heinrich, S | 1 |
| DeOliveira, ML | 1 |
| Jochum, W | 1 |
| Weishaupt, D | 1 |
| Frauenfelder, T | 1 |
| Graf, R | 1 |
| Clavien, PA | 1 |
| Coimbra, R | 1 |
| Porcides, RD | 1 |
| Melbostad, H | 1 |
| Loomis, W | 1 |
| Tobar, M | 1 |
| Hoyt, DB | 1 |
| Wolf, P | 1 |
| Turan, F | 1 |
| Kaptanoglu, L | 1 |
| Kapan, M | 1 |
| Kapan, S | 1 |
| Goksoy, E | 1 |
| Oktar, H | 1 |
| Ratia Giménez, T | 1 |
| Navidad Novalvos, R | 1 |
| Martínez Onturbe, P | 1 |
| Santamaría Solís, LV | 1 |
| Castillo Olivares Ramos, JL | 1 |
| Shibayama, Y | 1 |
| Asaka, S | 1 |
| Nakata, K | 1 |
| Koczorek, M | 1 |
| Koppenhagen, K | 1 |
| Wenig, HG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia[NCT01774487] | Phase 2 | 17 participants (Actual) | Interventional | 2013-02-04 | Terminated (stopped due to Target enrollment was not reached because the medication, pentoxifylline, has a taste that is not well tolerated by infants. The study team decided to end the study before meeting the enrollment goal because of the medication taste.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will record the ALT levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 14-45 U/L, with a higher level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | U/L (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 160 |
The investigators will track the weight of patients over the course of therapy in patients receiving 90 days of PTX (this is recorded as part of routine clinical care). The weight will then be compared to standards to calculate a z-score. Normal weight Z-score is greater than or equal to 0, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 0 |
| Group 2 | 0 |
The investigators will track the serum conjugated bilirubin (CB) levels over the course of therapy in patients receiving 90 days of PTX (this laboratory test is drawn as part of routine care). Normal CB is 0.0-0.3 mg/dL, with a higher number of patients meeting this indicating a better outcome. (NCT01774487)
Timeframe: 12 weeks after starting therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentoxifylline - Group 1 | 6 |
| Pentoxifylline - Group 2 | 0 |
The investigators will record platelet levels at age two years, in patients who had previously been treated with PTX therapy and still have their native liver. Scale 189-403*10^3 Platelets/μL, with a lower level indicating a worse outcome. (NCT01774487)
Timeframe: 2 years of age
| Intervention | 10^3 Platelets/μL (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 208 |
"The investigators will measure spleen size by ultrasound at 2 years of age, in patients who had received PTX therapy earlier and still have their native liver. Normal spleen size range (10th-90th percentile) at this age is 6.4-8.6 cm, with a value exceeding this range indicating a worse outcome." (NCT01774487)
Timeframe: 2 years of age
| Intervention | cm (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 10.0 |
The investigators will track time to liver transplant. The shorter time to liver transplant indicates a worse outcome. (NCT01774487)
Timeframe: Baseline and up to two years after therapy finishes
| Intervention | days (Mean) |
|---|---|
| Pentoxifylline - Group 1 | 317 |
| Pentoxifylline - Group 2 | 273 |
2 reviews available for pentoxifylline and Liver Dysfunction
| Article | Year |
|---|---|
Pentoxifylline in liver ischemia and reperfusion.
Topics: Animals; Apoptosis; Humans; Ischemia; Liver; Liver Diseases; Liver Transplantation; Pentoxifylline; | 2014 |
New paradigms in management of alcoholic hepatitis: a review.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Fecal Microbiota Transplantation; Female | 2017 |
2 trials available for pentoxifylline and Liver Dysfunction
| Article | Year |
|---|---|
Effects of pentoxifylline on liver regeneration: a double-blinded, randomized, controlled trial in 101 patients undergoing major liver resection.
Topics: Biopsy; Double-Blind Method; Female; Hepatectomy; Humans; Infusions, Intravenous; Interleukin-6; Liv | 2010 |
[The effect of pentoxifylline on liver perfusion: a comparative study in patients with liver diseases and in normal subjects, using 198Au-colloid-scintigraphy (author's transl)].
Topics: Adult; Aged; Chronic Disease; Female; Hepatitis; Humans; Liver; Liver Circulation; Liver Cirrhosis; | 1979 |
8 other studies available for pentoxifylline and Liver Dysfunction
| Article | Year |
|---|---|
Pentoxifylline enhances the protective effects of hypertonic saline solution on liver ischemia reperfusion injury through inhibition of oxidative stress.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Capillary Permeability; Disease Models, | 2015 |
Liver lipid peroxidation and antioxidant capacity in cerulein-induced acute pancreatitis.
Topics: Acute Disease; Animals; Arginine; Ceruletide; Female; Free Radical Scavengers; Lipid Peroxidation; L | 2009 |
Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Endotoxemia; Immunohistochemistry; Inter | 2005 |
Comparative effects of several therapatic agents on hepatic damage induced by acute experimental pancreatitis.
Topics: Acetylcysteine; Acute Disease; Animals; Antioxidants; Arginine; Ascorbic Acid; Ceruletide; Female; L | 2008 |
Effects of nimodipine and pentoxyfylline in prevention of hepatic ischemic damage in rats at normal and hypothermic conditions.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Calcium Channel Blockers; Hypothermia; L | 2008 |
[Liver damage due to normothermic ischemia and reperfusion in the rat. The effects of pentoxifylline pretreatment].
Topics: Animals; Drug Evaluation, Preclinical; Ischemia; Liver; Liver Diseases; Male; Necrosis; Pentoxifylli | 1995 |
Role of activated macrophages in augmentation of endotoxin hepatotoxicity.
Topics: Animals; Chemical and Drug Induced Liver Injury; Endotoxins; Liver Diseases; Macrophage Activation; | 1994 |
[Chronic liver diseases. The nihilism has gone].
Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; | 2001 |